Clinical Trial Update: A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006) [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update on the safety and tolerability of miransertib (MK-7075) in participants with PIK3CA-related overgrowth spectrum or Prote…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pik3ca-related Overgrowth Spectrum
• Proteus Syndrome

Drugs mentioned

• Miransertib (Miransertib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) | Phase 2 | Status: ACTIVE_NOT_RECRUITING